Imperagen Lands €5.8M to Scale Enzyme Engineering

The big picture: Imperagen, a Manchester-based BioTech company leveraging AI and quantum physics for enzyme engineering, has secured €5.7 million (£5 million) in Seed funding. This capital will accelerate R&D, expand wet lab capabilities, and build out its go-to-market function over the next 18 months.

Why it matters:

• Accelerated Innovation: The funding enables Imperagen to significantly advance its R&D efforts, crucial for developing novel enzyme designs that can transform various industrial and life science applications.
• Market Expansion: With new leadership and expanded capabilities, Imperagen aims to convert growing commercial interest into contracted revenue across key sectors like pharmaceuticals, personal care, and sustainable fine chemicals.
• Regional Growth: The investment, partly from the GMC Life Sciences Fund and Northern Powerhouse Investment Fund II, reinforces the North West UK’s burgeoning life sciences ecosystem and supports local hiring and growth.

How it works:

• Quantum-AI Integration: Imperagen’s proprietary platform combines quantum physics simulations to generate vast datasets of mutation combinations, which then train problem-specific AI models.
• Closed-Loop Learning: Automated robotics test the AI’s highest-performing predictions in the lab, generating real-world data that continuously feeds back into and refines the AI model.
• Predictive Design: This iterative feedback loop allows the system to learn from each experiment, narrowing down to the most effective enzyme variants with high predictability and speed, significantly outperforming traditional and zero-shot methods.

The catch: While Imperagen’s integrated approach promises superior predictability and speed, the enzyme engineering market is highly competitive, with both established traditional methods and emerging AI-driven techniques. The challenge lies in consistently demonstrating its platform’s superior performance and cost-effectiveness at scale to industrial clients who have historically relied on slower, but proven, manual screening or less reliable zero-shot methods.